ICS-LABA

Phase 2Small molecule

Incyte

ICS-LABA is one of 23 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

Moderate to Severe AsthmaActive, not recruiting

AsthmaPhase 2

Active, not recruiting

Moderate to Severe AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Spiriva

Boehringer Ingelheim

Preclinical

8 2

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 3

Formoterol Fumarate

AstraZeneca

Preclinical

8 4

Symbicort

AstraZeneca

Preclinical

6 5

Atrovent

Boehringer Ingelheim

Preclinical

2 6

Aciphex

Akero Therapeutics

Preclinical

2 7

ICS-LABA

Incyte

Phase 2

1 8

Tylenol

KKenvue Brands

Preclinical

1 9

Paracetamol

GSK

Preclinical

1 10

Aclidinium Bromide

AstraZeneca

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Moderate to Severe Asthma

NCT05851443

Clinical

Trials by Indication[1]

Moderate to Severe Asthma1 trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Active, not recruiting· Incyte logo

Incyte·Phase 2·NCT05851443·247 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ICS-LABA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ICS-LABA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ICS-LABA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Incyte

ICS-LABA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Moderate to Severe Asthma1 trial

References

Drug Info

Quick Facts

Related News